First Time Loading...
S

Santhera Pharmaceuticals Holding AG
SIX:SANN

Watchlist Manager
Santhera Pharmaceuticals Holding AG
SIX:SANN
Watchlist
Price: 9.32 CHF -0.53%
Updated: May 3, 2024

Santhera Pharmaceuticals Holding AG
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Santhera Pharmaceuticals Holding AG
Revenue Peer Comparison

Comparables:
ADCT
CRSP
BSLN
IDIA
KURN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
S
Santhera Pharmaceuticals Holding AG
SIX:SANN
Revenue
CHf7.5m
CAGR 3-Years
-54%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Revenue
$69.6m
CAGR 3-Years
N/A
CAGR 5-Years
129%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Revenue
$371.2m
CAGR 3-Years
709%
CAGR 5-Years
160%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Revenue
CHf157.6m
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
14%
Idorsia Ltd
SIX:IDIA
Revenue
CHf97.1m
CAGR 3-Years
60%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Revenue
CHf33.6m
CAGR 3-Years
103%
CAGR 5-Years
116%
CAGR 10-Years
N/A

See Also

What is Santhera Pharmaceuticals Holding AG's Revenue?
Revenue
7.5m CHF

Based on the financial report for Dec 31, 2022, Santhera Pharmaceuticals Holding AG's Revenue amounts to 7.5m CHF.

What is Santhera Pharmaceuticals Holding AG's Revenue growth rate?
Revenue CAGR 5Y
-20%

The average annual Revenue growth rates for Santhera Pharmaceuticals Holding AG have been -54% over the past three years , -20% over the past five years .